Enhanced renal function in bradykinin B2 receptor transgenic mice

被引:28
作者
Wang, DZ [1 ]
Yoshida, H [1 ]
Song, Q [1 ]
Chao, L [1 ]
Chao, J [1 ]
机构
[1] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA
关键词
nitric oxide; guanosine; 3; 5 '-cyclic monophosphate; adenosine; kinin; human bradykinin B(2) receptor;
D O I
10.1152/ajprenal.2000.278.3.F484
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The tissue kallikrein-kinin system has been recognized as a paracrine and/or autocrine hormonal system that regulates arterial pressure, renal hemodynamics, and electrolyte excretion. We have created a transgenic mouse model overexpressing human bradykinin B(2) receptor, and the mice developed lifetime hypotension. With this animal model, we further analyzed the potential role of B(2) receptors in regulation of renal function. Baseline urinary excretion, urinary potassium excretion, and pH were significantly increased in transgenic mice, whereas urinary sodium excretion and serum sodium concentration were unaltered. Transgenic mice exhibited increased renal blood flow glomerular filtration rate, and urine flow. Enhanced renal function was accompanied by significant increases in urinary nitrate/nitrite, cGMP, and cAMP levels with unaltered urinary kinin levels in transgenic mice compared with control siblings. Renal cGMP and cAMP content was also significantly increased in transgenic mice. Because the renin-angiotensin system exerts vasoconstriction buffering vasodilation of the kallikrein-kinin system, expression of renin-angiotensin components was examined by Northern blot analysis. We found a significant increase in hepatic angiotensinogen expression with no changes in renal renin and pulmonary angiotensin-converting enzyme mRNA levels in B(2) receptor transgenic mice. These studies showed that overexpression of B(2) receptors in transgenic mice resulted in hypotension and enhanced renal function through activation of nitric oxide-cGMP and cAMP signal transduction pathways.
引用
收藏
页码:F484 / F491
页数:8
相关论文
共 54 条
[1]   MECHANISMS UNDERLYING THE INHIBITORY EFFECT OF DIBUTYRYL-CYCLIC-AMP IN VASCULAR SMOOTH-MUSCLE [J].
ABE, A ;
KARAKI, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 211 (03) :305-311
[2]   ABNORMALITIES IN KALLIKREIN EXCRETION IN SPONTANEOUSLY HYPERTENSIVE RATS [J].
ADER, JL ;
POLLOCK, DM ;
BUTTERFIELD, MI ;
ARENDSHORST, WJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 248 (03) :F396-F403
[3]   Salt-sensitive hypertension in bradykinin B-2 receptor knockout mice [J].
Alfie, ME ;
Yang, XP ;
Hess, F ;
Carretero, OA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 224 (03) :625-630
[4]   Role of angiotensin II and bradykinin in experimental diabetic nephropathy - Functional and structural studies [J].
Allen, TJ ;
Cao, ZM ;
Youssef, S ;
Hulthen, UL ;
Cooper, ME .
DIABETES, 1997, 46 (10) :1612-1618
[5]   Current concepts of renal hemodynamics in diabetes [J].
Anderson, S ;
Vora, JP .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1995, 9 (04) :304-307
[6]   A GENE FOR HIGH URINARY KALLIKREIN MAY PROTECT AGAINST HYPERTENSION IN UTAH KINDREDS [J].
BERRY, TD ;
HASSTEDT, SJ ;
HUNT, SC ;
WU, LL ;
SMITH, JB ;
ASH, KO ;
KUIDA, H ;
WILLIAMS, RR .
HYPERTENSION, 1989, 13 (01) :3-8
[7]  
Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1
[8]   Molecular responses of endothelial tissue to kinins [J].
Busse, R ;
Fleming, I .
DIABETES, 1996, 45 :S8-S13
[9]  
CARRETERO OA, 1991, HYPERTENSION S1, V18, P158
[10]   New experimental evidence for a role of tissue kallikrein in hypertension [J].
Chao, J ;
Chao, L .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (08) :1569-1574